2022. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s47. DOI:https://doi.org/10.25251/skin.6.supp.47.